Literature DB >> 19530980

Treatment patterns and symptom control in patients with GERD: US community-based survey.

William D Chey1, Reema R Mody, Eric Q Wu, Lei Chen, Smita Kothari, Bjorn Persson, Nicolas Beaulieu, Mei Lu.   

Abstract

BACKGROUND: Proton pump inhibitors (PPIs) are the most commonly used pharmacological treatment for gastroesophageal reflux disease (GERD).
OBJECTIVE: To examine the utilization patterns of PPIs and other GERD-related medications, satisfaction with PPI treatment and presence of GERD symptoms. PATIENTS AND METHODS: GERD patients using prescription PPIs were identified from a mixed-model HMO health plan. Utilization patterns of PPIs and other GERD medications, satisfaction with PPI treatment and presence of GERD symptoms were assessed using questionnaires.
RESULTS: Among the 617 patients who completed the survey, 71.0% used PPIs once a day (QD), 22.2% used twice a day (BID) and 6.8% more than twice a day or on an as-needed basis. Approximately 42.1% of all patients supplemented their prescription PPIs with other GERD medications, including over-the-counter medications and H(2)-receptor antagonists. Over 85% of the patients still experienced GERD symptoms and 82.7% nighttime symptoms. Overall, 72.8% of all patients were satisfied or very satisfied with their PPI treatment. LIMITATIONS: The study used self-reported data which may have been subject to recall bias. As the study was conducted in a specific region of the US, the results may have limited generalizability to other US regions or countries.
CONCLUSIONS: Patients on PPI treatment often experience GERD symptoms and supplement their prescription PPIs with other GERD medications. A substantial proportion of GERD patients receiving PPI treatment are on a BID regimen. Furthermore, more than a quarter of the patients are not completely satisfied with their PPI treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19530980     DOI: 10.1185/03007990903035745

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  20 in total

1.  The value of branded proton pump inhibitors: formulary considerations.

Authors:  David A Peura; Rosemary R Berardi; Javier Gonzalez; Louis Brunetti
Journal:  P T       Date:  2011-07

Review 2.  Management of the patient with incomplete response to PPI therapy.

Authors:  Peter J Kahrilas; Guy Boeckxstaens; Andre J P M Smout
Journal:  Best Pract Res Clin Gastroenterol       Date:  2013-06       Impact factor: 3.043

3.  Many patients continue using proton pump inhibitors after negative results from tests for reflux disease.

Authors:  Andrew J Gawron; Jami Rothe; Angela J Fought; Anita Fareeduddin; Erin Toto; Lubomyr Boris; Peter J Kahrilas; John E Pandolfino
Journal:  Clin Gastroenterol Hepatol       Date:  2012-02-22       Impact factor: 11.382

Review 4.  Patient satisfaction with medication for gastroesophageal reflux disease: a systematic review.

Authors:  Sander Jo van Zanten; Catherine Henderson; Nesta Hughes
Journal:  Can J Gastroenterol       Date:  2012-04       Impact factor: 3.522

Review 5.  The Quality of Care for Gastroesophageal Reflux Disease.

Authors:  Rena Yadlapati; Lara Dakhoul; John E Pandolfino; Rajesh N Keswani
Journal:  Dig Dis Sci       Date:  2016-12-27       Impact factor: 3.199

6.  The influence of gut microbiome on progression of overactive bladder symptoms: a community-based 3-year longitudinal study in Aomori, Japan.

Authors:  Yoshiharu Okuyama; Teppei Okamoto; Daichi Sasaki; Kai Ozaki; Jung Songee; Shingo Hatakeyama; Tatsuya Mikami; Chikara Ohyama
Journal:  Int Urol Nephrol       Date:  2021-10-29       Impact factor: 2.370

Review 7.  Economic evaluations of gastroesophageal reflux disease medical management.

Authors:  Andrew J Gawron; Dustin D French; John E Pandolfino; Colin W Howden
Journal:  Pharmacoeconomics       Date:  2014-08       Impact factor: 4.981

8.  Laparoscopic fundoplication for refractory GERD: a procedure worth repeating if needed.

Authors:  Zia Kanani; Jon C Gould
Journal:  Surg Endosc       Date:  2020-02-03       Impact factor: 4.584

Review 9.  Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis.

Authors:  Allison A Lambert; Jennifer O Lam; Julie J Paik; Cesar Ugarte-Gil; M Bradley Drummond; Trevor A Crowell
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

10.  Comparison of health care resource utilization and costs among patients with GERD on once-daily or twice-daily proton pump inhibitor therapy.

Authors:  Reema Mody; Debra Eisenberg; Likun Hou; Siddhesh Kamat; Joseph Singer; Lauren B Gerson
Journal:  Clinicoecon Outcomes Res       Date:  2013-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.